Trump announces trade deal with EU following months of negotiations
DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN), currently trading at $10.33 with a market capitalization of $214 million, has announced that it is now in full compliance with Nasdaq’s continued listing standards, following a successful adjustment of its average closing share price. The pharmaceutical company, focused on cardiovascular disease management, received confirmation from Nasdaq on April 29, 2025, that its common stock maintained a minimum average closing share price of $1.00 over the preceding 10 business days.
This development secures Amarin’s public listing on the Nasdaq Capital Market, alleviating concerns about its ability to meet the exchange’s minimum bid price requirement. According to InvestingPro data, the company maintains a healthy financial position with a strong current ratio of 3.31, indicating robust liquidity. Aaron Berg, President & CEO of Amarin, expressed relief at this outcome, emphasizing the company’s commitment to enhancing the global value of its flagship product, VASCEPA/VAZKEPA, for patients with cardiovascular issues.
Amarin, with its headquarters in New Jersey, United States, and additional offices in Ireland, Switzerland, and other European locations, continues to focus on addressing cardiovascular risks that persist beyond traditional therapies. The company is scheduled to report its next earnings on April 30, 2025. InvestingPro analysis reveals several key insights about the company’s financial health, with 6 additional ProTips available to subscribers.
The company has cautioned investors against placing undue reliance on forward-looking statements, which are subject to risks and uncertainties. Amarin has made it clear that it will not update forward-looking statements based on new information or future events.
This announcement, based on a press release statement, marks an important milestone for Amarin as it works to maintain its market presence and fulfill its mission in the pharmaceutical industry. For deeper insights into Amarin’s financial health and future prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Amarin Corporation has made several strategic announcements. The company will implement a ratio change for its American Depositary Shares, adjusting from one ADS representing one ordinary share to one ADS representing twenty ordinary shares. This move aims to meet Nasdaq’s minimum bid price requirement. Additionally, Amarin has appointed Michael Torok, an investment expert and Co-Founder of JEC Capital Partners, to its Board of Directors. In a related development, board member Mark DiPaolo will not seek re-election and will step down following the 2025 Annual Meeting of Shareholders.
Amarin is also facing pressure from major shareholders, including Bradley L. Radoff and Michael Torok, who have urged the company to conduct a strategic review to maximize shareholder value. Furthermore, Amarin plans to present new in vitro data on its cardiovascular drug at the American College of Cardiology Annual Scientific Session & Expo. This presentation will focus on the mechanistic activities of eicosapentaenoic acid, the active ingredient in its product VASCEPA/VAZKEPA, which is used to reduce cardiovascular events. These developments are part of Amarin’s ongoing efforts to enhance its market position and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.